Table 2.

Association between BMI and iloprost tolerance in patients with systemic sclerosis.

Model	BMI, −β (95% CI)	p value
Unadjusted	−0.024 (−0.040 to −0.007)	<0.001
Model 1	−0.026 (−0.043 to −0.009)	0.003
Model 2	−0.025 (−0.042 to −0.007)	0.006
Model 3 (fully adjusted)	−0.021 (−0.039 to −0.003)	0.020

Model 1 adjusted for gender, age, disease duration, and smoking habit. Model 2 adjusted for gender, age, disease duration, smoking habit, disease pattern (diffuse versus limited cutaneous involvement), calcinosis, and ulcers before the beginning of the iloprost treatment. Model 3 (main model) adjusted for gender, age, disease duration, smoking habit, disease pattern (diffuse versus limited cutaneous involvement), calcinosis, ulcers before the beginning of the iloprost treatment, and concomitant therapy with CCB and PDE5i.

BMI, body mass index; CCB, calcium channel blocker; PDE5i, phosphodiesterase 5 inhibitors.